Tag: biosimilar

Sandoz: repurchase of a biosimilar in ophthalmology

(CercleFinance.com) – Sandoz announces that it has signed an agreement to acquire the American ranibizumab biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences, for a payment of $170 million. Cimerli is interchangeable…

Novartis: green light for a Sandoz biosimilar for MS

(CercleFinance.com) – Sandoz, the generics and biosimilars division of Novartis in the process of being spun off, announces that the United States FDA has approved the biosimilar Tyruko (natalizumab-sztn), developed…

Novartis: Positive data for an Eylea biosimilar

Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…

Novartis: positive data for an Eylea biosimilar

(CercleFinance.com) – Sandoz, a subsidiary of Novartis in the process of being spun off, announces the positive results of the Phase III efficacy and safety confirmation study MYLIGHT for its…

Novartis: positive opinion for a biosimilar in MS

(CercleFinance.com) – Sandoz, the generics and biosimilars division of Novartis in the process of being spun off, announces that the CHMP of the European Medicines Agency recommends the marketing authorization…

Novartis: BLA accepted for a biosimilar in MS

Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…